Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is among the best medical AI stocks to buy now. On March 31, Recursion moved to ...

Recursion Pharmaceuticals expanded its collaboration with Citeline to integrate real world data into its AI enabled ClinTech Platform. The partnership is aimed at refining clinical trial design and ...

Recursion Pharmaceuticals executives discussed the company’s artificial intelligence-driven drug discovery platform during a ...

Recursive Superintelligence raises $500M to accelerate AI innovation, signaling strong investor confidence in next-gen ...

Recursion Pharmaceuticals, Inc. (RXRX) 25th Annual Needham Virtual Healthcare Conference April 13, 2026 12:45 PM EDTCompany ParticipantsBen Taylor - ...

Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with Recursion (NASDAQ: RXRX), a leading tech-bio company decoding biology ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.60, marking a -4% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.26%.

While the advent of artificial intelligence (AI) has obviously changed the world, not every utilization of AI has necessarily ...

OpenAI is rolling out an early version of an artificial intelligence model designed to accelerate drug discovery, joining a ...

The technology sector is no longer asking what artificial intelligence can do for us. It is asking what AI can do for itself.